CClinicalTrials.gg
Active, not recruitingNCT03522025Updated Sep 25, 2025

GMK-UNI Anatomical UKA: Fixation of Cemented vs Cementless Designs

An interventional study of Unicompartmental Knee Arthroplasty (UKA) in Osteoarthritis, Knee, sponsored by Medacta International SA. Active, not recruiting at 5 sites in 2 countries. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by Medacta International SA · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 95 Years
Sex
All
01

Study summary

Unicompartmental knee arthroplasty (UKA) is the principal surgical alternative to the total knee arthroplasty (TKA) in patients with end-stage unicompartmental tibiofemoral osteoarthritis (OA) of the knee. The current comparative randomized study aims to evaluate the fixation of cemented and cementless designs of GMK-UNI unicompartmental knee prosthesis over a 5-year time period.

Read the detailed description

The Primary objective is to compare the quality of fixation of cemented and cementless designs of GMK-UNI unicompartmental knee replacement at 2 years of follow-up.

The Secondary objectives include the evaluation of the patient improvement (subjective and objective) using the new Knee Society Score (KSS); the patient's anterior pain following UKA and any eventual patella-femoral disorder; Implant survival rate using the Kaplan Meier analysis; Post-op radiological findings and Adverse Events.

The Primary outcome aims to compare the occurrence of radiolucency's lines (both partial and complete) between the two study groups. Secondary outcomes include New KSS, OKS, Kaplan Meier analysis and stability and fixation of UNI prosthesis.

All patients who meet the inclusion criteria to take part in the current clinical study will be invited to participate before the surgery.

Subjects will be randomized during the screening; half of them will receive the cemented GMK-UNI anatomical UKA and the other half the cementless GMK-UNI anatomical UKA.

Clinical data will be recorded on CRF at those time-points:

  • Before the surgery
  • During the surgery
  • After the surgery at 3 months, 1, 2, 3 and 5 years.
02

Conditions studied

  • Osteoarthritis, Knee
03

In context

Osteoarthritis, Knee

3,302 studies on the registry are indexed under Osteoarthritis, Knee; 608 are open to participants now.

This study's enrollment of 70 is close to the median of 70 across 2,731 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Medacta International SA is the lead sponsor of 46 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with end-stage unicompartmental tibiofemoral osteoarthritis (OA) of the knee that meet the indications for use according to Medacta implants included in this study (on-label use);
  • Those suffering from unilateral osteoarthritis or osteonecrosis of the medial compartment;
  • Frontal deformity \< 10° (evaluated on weight-bearing long-axis x-rays);
  • Flexion contracture \< 10°;
  • Intact ligaments;
  • Patients who are willing and able to provide written informed consent for participation in the study. Written informed consent must be obtained prior to the patient's surgery;
  • Patient's age over 18 years old;
  • Patient with BMI \< 40 kg/m2;
  • Patients must be willing to comply with the pre and post-operative evaluation schedule.

Exclusion criteria

Exclusion criteria:

  • Patients with one or more medical conditions identified as a contraindication defined by the labelling on any Medacta implants used in this study;
  • Any patient who cannot or will not provide informed consent for participation in the study;
  • Patients who need to undergo lateral unicompartmental knee arthroplasty;
  • Patients who need a revision surgery;
  • Patients who need a patella-femoral joint prosthesis;
  • Patients who had previously undergone high tibial osteotomy or ACL reconstruction;
  • Patients with BMI ≥ 40 kg/m2;
  • Patients unable to understand and take action;
  • Any case not described in the inclusion criteria;
  • Patients aged under 18 years;
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Active comparator
    GMK-UNI cemented fixation prosthesis

    Unicompartmental Knee Arthroplasty (UKA)

    Device: Unicompartmental Knee Arthroplasty (UKA)

  • Experimental
    GMK-UNI cementless fixation prosthesis

    Unicompartmental Knee Arthroplasty (UKA)

    Device: Unicompartmental Knee Arthroplasty (UKA)

Interventions

  • DeviceUnicompartmental Knee Arthroplasty (UKA)

    Unicompartmental Knee Arthroplasty (UKA) is a less invasive treatment option compared to Total Knee Arthroplasty (TKA) for patients with primary anteromedial knee osteoarthritis.

06

What researchers measure

Primary outcomes

  1. Comparing the occurrence of radiolucency's lines

    Compare occurrence of radiolucency's lines (both partial and complete)between the two study groups

    Time frame: 5 yrs

Secondary outcomes

  1. Anterior Knee Pian Scale (Kujala score)

    It's a 13-item knee specific self-report questionnaire. It documents response to 6 activities associated with anterior knee pain as well as symptoms such as limp, inability to weight bear through the affected limp, swelling...). It asks about duration of symptoms and limbs affected. Max score is 100 and lower scores indicate greater pain/disability. Scoring is hierarchical using various types of categorisation including "no difficulty-unable " and "no pain-severe pain". It is easy to understand and takes few minutes to complete.It has a good test-retest reliability.

    Time frame: pre-op; 3months;1,2,3,5 yrs

  2. Implant survival rate using Kaplan Meier analysis

    Implant survival rate

    Time frame: 5 yrs

  3. Recording of adverse events

    Any complication occurred during the study

    Time frame: Throughout the study

  4. Oxford Knee Score

    The Oxford Knee Score (OKS) is a 12-item patient-reported PRO specifically designed and developed to assess function and pain after total knee replacement (TKR) surgery (arthroplasty).Each question is scored from 1 to 5, with 1 representing best outcome/least symptoms. Scores from each question are added so the overall score is from 12 to 60 (12 being the best outcome). The overall score for the OKS is acquired by simply summing the scores received for individual questions.

    Time frame: Pre-op;3month;1,2,3,5yrs

  5. New Knee Society Score

    The new KSS System is a validated and responsive method for assessing objective and subjective outcomes after total and partial knee arthroplasty.It includes versions to be admninstered pre-op and post-op.It has an initial assessment of demographic deatils. The objective knee score includes VAS score of pain walking on level ground and on stairs or inclines, as well as ROM, an assessment of alignment, ligament stability along with deductions for flexion contracture or extensor lag. Pts then record their satisfaction, functional activities and expectations. It consists of 4 subscales: 1) objective knee score (7 items;100 points); 2) Satisfaction Score (5 items; 40 points);3) Expectation Score (3 items; 15 points); 4) Functional Activity Score (19 items; 100 points)

    Time frame: Pre-op:3months;1,2,3,5 yrs

  6. Stability and fixation of unicompartmental prosthesis

    To evaluate the stability and fixation of the prosthesis

    Time frame: 5 yrs

07

Study locations

5 sites
  • Clinique Saint Vincent de Paul
    Bourgoin, France 38300, France
  • Clinique du Mail
    La Rochelle, France 17000, France
  • Centre Orthéo, Espace Fauriel
    Saint-Etienne, France 42100, France
  • CHP Saint-Grégoire
    Saint-Grégoire, France 35760, France
  • Dr. Näder Helmy
    Solothurn, Switzerland 4500, Switzerland
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03522025
Lead sponsor
Medacta International SA
Responsible party
Sponsor
First posted
May 11, 2018
Start date
Feb 15, 2019
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Sep 25, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion